Folgen
Manish Muhuri
Manish Muhuri
Affiliate Instructor, University of Massachusetts Medical School
Bestätigte E-Mail-Adresse bei umassmed.edu - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses
YK Chan, SK Wang, CJ Chu, DA Copland, AJ Letizia, H Costa Verdera, ...
Science translational medicine 13 (580), eabd3438, 2021
1822021
Overcoming innate immune barriers that impede AAV gene therapy vectors
M Muhuri, Y Maeda, H Ma, S Ram, KA Fitzgerald, PWL Tai, G Gao
The Journal of clinical investigation 131 (1), 2021
1452021
Durability of transgene expression after rAAV gene therapy
M Muhuri, DI Levy, M Schulz, D McCarty, G Gao
Molecular Therapy 30 (4), 1364-1380, 2022
782022
EGF hijacks miR-198/FSTL1 wound-healing switch and steers a two-pronged pathway toward metastasis
GM Sundaram, HM Ismail, M Bashir, M Muhuri, C Vaz, S Nama, GS Ow, ...
Journal of Experimental Medicine 214 (10), 2889-2900, 2017
702017
Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles
A Biscans, J Caiazzi, N McHugh, V Hariharan, M Muhuri, A Khvorova
Molecular Therapy 29 (4), 1382-1394, 2021
602021
Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity
Y Xiao, M Muhuri, S Li, W Qin, G Xu, L Luo, J Li, AJ Letizia, SK Wang, ...
JCI insight 4 (13), 2019
412019
MicroRNA-138 is a prognostic biomarker for triple-negative breast cancer and promotes tumorigenesis via TUSC2 repression
S Nama, M Muhuri, F Di Pascale, S Quah, L Aswad, M Fullwood, ...
Scientific reports 9 (1), 12718, 2019
362019
Vectored immunotherapeutics for infectious diseases: Can rAAVs be the game changers for fighting transmissible pathogens?
W Zhan, M Muhuri, PWL Tai, G Gao
Frontiers in immunology 12, 673699, 2021
342021
Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection
VN Hariharan, M Shin, CW Chang, D O’Reilly, A Biscans, K Yamada, ...
Proceedings of the National Academy of Sciences 120 (11), e2219523120, 2023
312023
Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells
M Arjomandnejad, K Sylvia, M Blackwood, T Nixon, Q Tang, M Muhuri, ...
Molecular Therapy Methods & Clinical Development 23, 490-506, 2021
312021
Novel combinatorial microRNA-binding sites in AAV vectors synergistically diminish antigen presentation and transgene immunity for efficient and stable transduction
M Muhuri, W Zhan, Y Maeda, J Li, A Lotun, J Chen, K Sylvia, I Dasgupta, ...
Frontiers in Immunology 12, 674242, 2021
292021
C/EBPβ mediates RNA polymerase III-driven transcription of oncomiR-138 in malignant gliomas
F Di Pascale, S Nama, M Muhuri, S Quah, HM Ismail, XHD Chan, ...
Nucleic Acids Research 46 (1), 336-349, 2018
222018
DNA technology: a reference handbook
DE Newton
Bloomsbury Publishing USA, 2016
82016
Reducing AAV-mediated immune responses and pathology in a subretinal pig model by engineering the vector genome
YK Chan, S Wang, A Letizia, Y Chan, E Lim, A Graveline, HC Verdera, ...
Molecular Therapy 27 (4), 298-298, 2019
72019
Oncolytic virus alphavirus M1: a new and promising weapon to fight cancer
M Muhuri, G Gao
Human gene therapy 32 (3-4), 136-137, 2021
62021
Immunogenicity and toxicity of AAV gene therapy
A Bradbury, D Markusic, M Muhuri, L Ou
Frontiers in immunology 14, 1227231, 2023
52023
Is smaller better? Vaccine targeting recombinant receptor-binding domain might hold the key for mass production of effective prophylactics to fight the COVID-19 pandemic
M Muhuri, G Gao
Signal Transduction and Targeted Therapy 5 (1), 222, 2020
42020
Membranous Bubbles: High-Purity and High-Titer Exosomes as the Potential Solution for Adeno-Associated Viruses to Evade Neutralization?
M Muhuri, G Gao
Human Gene Therapy 32 (23-24), 1427-1429, 2021
22021
Use of novel miRNA-binding site cassettes for antigen-presenting cell detargeting of transgene expression by rAAV gene therapy vectors
G Gao, P Tai, M Muhuri, W Zhan
US Patent 11,655,483, 2023
12023
Novel Approaches in Engineering a Multipurpose AAV Vector Genome to Evade Both Innate and Adaptive Immune Responses
M Muhuri, J Xie, YK Chan, J Li, Q Su, AJ Letizia, GM Church, PWL Tai, ...
MOLECULAR THERAPY 28 (4), 181-181, 2020
12020
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20